Additional Indications. 20 3.9 Improvements .............................................. 21
Appears in 4 contracts
Sources: Exclusive License and Supply Agreement (Icn Pharmaceuticals Inc), Exclusive License and Supply Agreement (Icn Pharmaceuticals Inc), Exclusive License and Supply Agreement (Icn Pharmaceuticals Inc)
Additional Indications. 20 14 3.9 Improvements .............................................. 21..................................................... 15
Appears in 3 contracts
Sources: Exclusive License and Supply Agreement (Icn Pharmaceuticals Inc), Exclusive License and Supply Agreement (Ribapharm Inc), Exclusive License and Supply Agreement (Ribapharm Inc)